RGD Reference Report - Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer.

Authors: Grabsch, Heike  Dattani, Mit  Barker, Lisa  Maughan, Nicola  Maude, Karen  Hansen, Olaf  Gabbert, Helmut E  Quirke, Phil  Mueller, Wolfram 
Citation: Grabsch H, etal., Clin Cancer Res. 2006 Mar 1;12(5):1494-500. doi: 10.1158/1078-0432.CCR-05-2105.
RGD ID: 126790575
Pubmed: PMID:16533773   (View Abstract at PubMed)
DOI: DOI:10.1158/1078-0432.CCR-05-2105   (Journal Full-text)


PURPOSE: The double-strand break (DSB) is the major DNA lesion leading to chromosomal aberrations and faithful repair is crucial for maintaining genomic instability. Very little is known about the expression of DNA DSB repair proteins in colorectal cancer. To address this issue, we examined the expression pattern of DSB repair key proteins ATM, BRCA1, BRCA2, Ku70, and Ku80 and their putative role in patients survival in a large series of colorectal cancer.
EXPERIMENTAL DESIGN: 342 sporadic colorectal cancer were subjected to immunohistochemistry by using specific antibodies for the various proteins investigated. Staining results were compared with clinicopathologic data, patient survival, as well as expression of mismatch repair proteins MLH1 and MSH2.
RESULTS: The expression pattern of both ATM and BRCA1 predicted survival in all colorectal cancer patients as well as in the small subgroup of patients that received adjuvant therapy. Low expression of ATM and BRCA1 was associated with loss of MLH1 or MSH2 expression.
CONCLUSIONS: This is the first study to show a relationship between the expression of DNA DSB repair proteins ATM and BRCA1 and survival in colorectal cancer patients. Studies in tumors from large randomized trials are now necessary to validate our pilot data and establish the clinical usefulness of the immunohistochemical assay in predicting response to a particular adjuvant therapy regimen. Furthermore, our results indicate a possible link between expression of DNA mismatch repair and DNA DSB repair proteins in sporadic colorectal cancer, which warrants further investigation.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
ATMHumancolorectal cancer disease_progressionIEP  RGD 
AtmMousecolorectal cancer disease_progressionISOATM (Homo sapiens) RGD 
AtmRatcolorectal cancer disease_progressionISOATM (Homo sapiens) RGD 
BRCA1Humancolorectal cancer disease_progressionIEP  RGD 
BRCA2Humancolorectal cancer severityIEP  RGD 
Brca1Ratcolorectal cancer disease_progressionISOBRCA1 (Homo sapiens) RGD 
Brca1Mousecolorectal cancer disease_progressionISOBRCA1 (Homo sapiens) RGD 
Brca2Ratcolorectal cancer severityISOBRCA2 (Homo sapiens) RGD 
Brca2Mousecolorectal cancer severityISOBRCA2 (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Atm  (ATM serine/threonine kinase)
Brca1  (BRCA1, DNA repair associated)
Brca2  (BRCA2, DNA repair associated)

Genes (Mus musculus)
Atm  (ataxia telangiectasia mutated)
Brca1  (breast cancer 1, early onset)
Brca2  (breast cancer 2, early onset)

Genes (Homo sapiens)
ATM  (ATM serine/threonine kinase)
BRCA1  (BRCA1 DNA repair associated)
BRCA2  (BRCA2 DNA repair associated)


Additional Information